Shares of Senseonics Holdings, Inc. (SENS) surged 11.52% in after-hours trading on Wednesday, following the company's announcement of operational and financial updates, including the successful launch of its Eversense 365 continuous glucose monitoring (CGM) system and a positive outlook for 2025.
Senseonics reported preliminary unaudited fourth-quarter revenue of approximately $8.3 million and full-year 2024 revenue of around $22.5 million. The company highlighted several key achievements in 2024, including receiving FDA approval for and launching the Eversense 365 CGM system in collaboration with its commercial partner, Ascensia.
The launch of Eversense 365, which can monitor glucose levels for up to 365 days with a single implantable sensor, has been met with strong early interest. Senseonics noted a doubling of direct-to-consumer leads in Q4 compared to Q3, a record high of approximately 600 new patient shipments in December, a 49% increase in patients switching from competitive CGM systems, and a 118% surge in physician referrals since the launch.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。